about
Clinical implications of the intrinsic molecular subtypes of breast cancerNivolumab in previously untreated melanoma without BRAF mutationO6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study.A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.Genomic analysis and clinical management of adolescent cutaneous melanoma.Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trialSelumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Frequency and characteristics of familial melanoma in Spain: the FAM-GEM-1 Study.Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.SEOM guidelines for the management of Malignant Melanoma 2015Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma.Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.Development of Cutaneous Toxicities During Selective Anti-BRAF Therapies: Preventive Role of Combination with MEK Inhibitors.Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM).Infomelanoma 2020: an online digital application designed to assist health professionals for melanoma treatment.Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.SEOM clinical guideline for the management of malignant melanoma (2017).Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.Safety of vemurafenib in patients with BRAF V600 mutated metastatic melanoma: the Spanish experience.Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study.Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.
P50
Q26800996-6086C182-0E02-4322-910C-0F638D861EEBQ29620688-125735A8-138D-4337-8B11-1E82E9EB0FBFQ33334892-0830B62D-E9A0-4FCF-A22D-419D1AE1B4C1Q33414272-0E277C29-563D-4724-B706-B267F99A1129Q33701435-6A3E9ACD-B3A2-4CD6-8935-B97FCCA73686Q33749057-754613B7-6477-4BFE-8402-77ED5A5384E7Q34652628-BEF47876-4BBF-49E8-9EF0-7C146672490FQ34664981-D94E89F5-9A7E-447A-9629-0150699E844CQ35392953-542CB253-BF92-46D0-9C76-96FB58204A45Q35688401-C15894B3-0758-4100-9A04-460AEB15981AQ36371217-A86912BF-B846-4B3C-AC34-0372B9A68E5EQ36383626-6F72FECD-B15D-48FB-A3D8-F980813A8FAFQ36400221-6D9A2B90-7537-42EA-BC4A-1D55DCF8B858Q38617638-3E13C221-E77C-4296-9AF8-F77D030405F2Q38727030-25094A95-9220-4A0F-8A04-674BD9125E08Q38737680-2366543E-729A-4E1A-AE94-EA1BF750A817Q38773770-88E397E0-17E5-44AC-A246-DC12249BE745Q38802138-3FE5969D-D8D0-4933-B5D6-BA31FE1B3FD2Q38825707-7AA6B09F-5A10-406B-A266-AD687BF023C1Q39039083-32C0A8F8-C69B-483C-976E-862D358F69D2Q39043736-F83846F6-804F-4546-8008-E72F2E084308Q39174229-C67A0CAE-34B5-4703-8C24-0B29A2A14EEBQ39821273-89FE2496-6BC5-4DAE-A367-98C4ADB60194Q40578614-0FC6B777-6118-42C4-BF3C-3B5D1B84F481Q40875359-38EC94B2-BEF4-4241-989E-15A708DEC0E5Q42495423-98B0AEEC-BEDA-48E7-A983-AFA2B5FC07ECQ42645881-8389240C-CEDA-48C0-A5F8-37FC247D4C11Q43796093-3300A019-C14D-47F1-B809-400DCCEF3A92Q45822425-5A363642-54B5-4BD8-BA28-52E33C50AEF7Q47114238-FD248866-B38A-43EE-8914-A7E09F8A7F6FQ47551890-77432C3D-A16B-4478-A510-308DD6CC6818Q47769675-53C31130-BC9A-419E-B9B5-DA19B50F3356Q47844950-4A39FBB9-143D-473C-B39B-A89211503468Q48044922-32F848E4-57DE-4D28-8E6D-268E4DC88820Q48342771-60BC74FD-EF22-456A-A63E-4814C500C769Q48556138-FD614827-2E5B-4D14-9F58-C48AA1C6EB69Q48828873-AF6E898A-7A13-43D6-AFDB-F7AE107ECB23Q49556867-115416CA-5900-4CFA-A25E-C68929740B17Q51080505-CCD2ABD8-FE8B-4495-BE5A-FBEBE317E6E9Q53827416-8AFBC6FA-0EC2-4E73-BD72-AA5D4160BDFA
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ana Arance
@ast
Ana Arance
@en
Ana Arance
@es
Ana Arance
@nl
type
label
Ana Arance
@ast
Ana Arance
@en
Ana Arance
@es
Ana Arance
@nl
prefLabel
Ana Arance
@ast
Ana Arance
@en
Ana Arance
@es
Ana Arance
@nl
P106
P21
P31
P496
0000-0003-2896-1957